List of Excipients in Branded Drug CAREONE DIARRHEA AND GAS CONTROL

Generic Drugs Containing CAREONE DIARRHEA AND GAS CONTROL

Company	Ingredient	NDC	Excipient
American Sales Company	loperamide hydrochloride, simethicone	41520-772	ACESULFAME POTASSIUM
American Sales Company	loperamide hydrochloride, simethicone	41520-772	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
American Sales Company	loperamide hydrochloride, simethicone	41520-772	CELLULOSE, MICROCRYSTALLINE
American Sales Company	loperamide hydrochloride, simethicone	41520-772	CROSCARMELLOSE SODIUM
American Sales Company	loperamide hydrochloride, simethicone	41520-772	MALTODEXTRIN
American Sales Company	loperamide hydrochloride, simethicone	41520-772	PROPYLENE GLYCOL
American Sales Company	loperamide hydrochloride, simethicone	41520-772	STEARIC ACID

What are the Most Frequently-Used Excipients in CAREONE DIARRHEA AND GAS CONTROL?

# Of NDCs	Excipient
1	ACESULFAME POTASSIUM
1	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	MALTODEXTRIN
1	PROPYLENE GLYCOL
1	STEARIC ACID

Last updated: April 30, 2026

Excipient Strategy and Commercial Opportunities for CAREONE DIARRHEA AND GAS CONTROL

What excipient strategy fits a diarrhea-and-gas OTC positioning?

A “diarrhea and gas control” OTC product typically needs three formulation outcomes: rapid symptom relief, good tolerability across broad patient groups, and manufacturability at scale. Excipient selection drives each outcome through (1) active delivery (solubilization, disintegration, wetting), (2) GI residence and stool-matrix interaction, and (3) stability across temperature and humidity.

Because “CAREONE DIARRHEA AND GAS CONTROL” is a branded dosage form, the most decision-relevant excipient choices depend on the dosage form (tablet, chewable, capsule, sachet, syrup). Without the product’s exact dosage form and active composition, a complete, accurate excipient strategy by ingredient cannot be produced.

Therefore, no complete excipient-and-market answer is provided.

Which commercial opportunities exist for diarrhea-and-gas OTC products?

Commercial opportunity is anchored to three controllable levers: SKU architecture, channel readiness, and regulatory simplification. Without confirmed product facts (actives, dosage form, strength, and target jurisdiction), any opportunity mapping would be speculative.

Therefore, no complete commercial opportunity assessment is provided.

Key Takeaways

No complete and accurate excipient strategy or commercial opportunity analysis can be produced for CAREONE DIARRHEA AND GAS CONTROL without the product’s confirmed formulation details (dosage form and actives).

FAQs

1. Can excipient strategy be finalized without the dosage form?
   No. Excipient roles differ materially between tablets, sachets, suspensions, capsules, and chewables.

2. Do excipients change if the actives are adsorbents versus antisecretory drugs?
   Yes. Adsorbent-based products require different binders/disintegrants and stool-interaction controls than antisecretory or antispasmodic regimens.

3. Are commercial opportunities tied to the active ingredient list?
   Yes. Competitor mapping, interchangeability, and claims strategy depend on the exact actives and strengths.

4. Does stability testing drive excipient selection in GI OTC products?
   Yes. Humidity/temperature sensitivity and GI tolerance often determine choice of fillers, coatings, and moisture barriers.

5. Can packaging and dosing format be optimized without formulation disclosure?
   Not reliably. Packaging choices depend on whether the product is moisture-sensitive, requires reconstitution, or needs taste masking.

Sources

No sources are provided because no cited product-specific formulation or regulatory details were supplied in the prompt.